Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

The randomized, phase 3 ICARIA-MM study investigated isatuximab (Isa) with pomalidomide and dexamethasone (Pd) versus Pd in patients with relapsed/refractory multiple myeloma and ≥2 prior lines. This prespecified subgroup analysis examined efficacy in patients with renal impairment (RI; estimated gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Miles Prince, H., Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, Sémiond, Dorothée, van de Velde, Helgi, Yong, Kwee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862055/
https://www.ncbi.nlm.nih.gov/pubmed/32444867
http://dx.doi.org/10.1038/s41375-020-0868-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862055/
https://www.ncbi.nlm.nih.gov/pubmed/32444867
http://dx.doi.org/10.1038/s41375-020-0868-z

Ejemplares similares